• Science and Research

  First Patients Dosed in Trial Testing MS1819-SD Plus PERT for CF-related Severe EPI, AzurRX Says

  Posted by cystic-fibrosis-news-moderator on October 25, 2019 at 11:30 am

  

   AzurRx has started dosing patients in a Phase 2 clinical trial testing MS1819-SD in combination with PERT in cystic fibrosis patients with severe EPI. Click here to read more about it.

  What do you think of this trial and its findings?

  cystic-fibrosis-news-moderator replied 4 years, 6 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply